Writing
Articles
Harm reduction, the psychedelic market, and AI, from the shelf to the lab. Most of these first ran on Entheology Project.
AI Psychosis and Psychedelics: A Risky Combination
When AI chats feed paranoia or a loss of reality testing, psychedelics can magnify the same risks. What to watch for.
Read the article
Eli Lilly Acquires AtaiBeckley for $3.8 Billion
Eli Lilly's deal for AtaiBeckley moves psychedelic medicine toward the mainstream, and raises questions about who it will serve.
Read the article
What Is EntheoDNA? The Science Behind Personalized Psychedelic Pharmacogenomics
Why two people can have very different experiences with the same substance, and what genetics has to do with it.
Read the article
The Hidden Dangers of Synthetic Alkaloids in Entheogenic Products
Products sold as mushrooms that contain synthetic alkaloids, the Diamond Shruumz illnesses, and why testing matters.
Read the article
4-ACO-DMT Shortage Leads to New Knockoffs – Mushroom Prices Plummet!
Cheap synthetic knockoffs are pushing out real mushroom extracts in head shops. The economics behind the shift.
Read the article
Is Sublingual Psilocin the Next Leap in Entheogenic Therapy?
What sublingual psilocin is, why people are interested in it, and the harm-reduction points to know first.
Read the article
Magic Mushrooms Safety: A Guide to Responsible Use and Populations at Risk
The real risks of magic mushrooms, from misidentified species to set and setting, and who should be most careful.
Read the article
The Power of GABA and Amanita Mushrooms in Shaping Depression, Sleep, Mood and Anxiety
How GABA and muscimol, the compound in Amanita mushrooms, relate to mood, sleep and anxiety, and the open questions.
Read the articleUncovering the Hidden Dangers of Underground Mushroom Chocolate Manufacturing
What can end up in underground mushroom chocolates, from contamination to inconsistent potency.
Read the article